Regulatory T cells: A review of manufacturing and clinical utility

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)904-915
Number of pages12
Issue number4
StatePublished - Apr 2022

Bibliographical note

Funding Information:
This work was supported by the Production Assistance for Cellular Therapies (PACT) program from NIH/NHLBI at University of Minnesota Molecular and Cellular Therapeutics Facility, PACT Contract # HHSN268201000008C. This publication was also supported by the NCI grant P01 CA065493. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding Information:
BRB receives remuneration as an advisor to Magenta Therapeutics and Blue Rock Therapeutics; Research funding from BlueRock Therapeutics, Rheos Medicines, Equilibre, Carisma, and is a co‐founder of Tmunity Therapeutics. CGB and JEW received research funding from BlueRock Therapeutics. TM, KLH, MLM, JSM, and DHM have disclosed no conflicts of interest. The authors alone are responsible for the content and writing of the article.


  • Humans
  • Quality Control
  • T-Lymphocytes, Regulatory

PubMed: MeSH publication types

  • Review
  • Journal Article
  • Research Support, N.I.H., Extramural

Cite this